PDS Biotechnology Virtual KOL Event: The VERSATILE-003 Phase 3 Trial and the Increasing Prevalence and Pathology of HPV16-Positive Head and Neck Cancer
| DATE: | December 17, 2024 |
|---|---|
| TIME: | 12:00 PM EST |
| LOCATION: | Virtual |
About The Event
Join PDS Biotechnology for a virtual Key Opinion Leader (“KOL”) event to discuss the pathology and growing prevalence of HPV16-positive head and neck squamous cell carcinoma (“HNSCC”) as well as the Company’s upcoming VERSATILE-003 Phase 3 clinical trial of Versamune® HPV + pembrolizumab for first-line treatment of recurrent and/or metastatic HPV16-positive HNSCC.
The KOL event will feature panel participants:
- Francis “Frank” Worden, M.D., Rogel Cancer Center, University of Michigan
- Kevin Harrington, MBBS, Ph.D., The Institute of Cancer Research, United Kingdom
The event will be moderated by Kirk Shepard, M.D., PDS Biotech’s Chief Medical Officer. A live question and answer session will follow the formal discussion.